Introduction {#Sec1}
============

In recent years the number of *Clostridium difficile* infections (CDI) increased markedly in hospitals (hospital-acquired CDI) as well as outside hospitals (community-acquired CDI). Since 2003, hypervirulent strains of *C. difficile* belonging to PCR ribotypes 078 and 027 have been found in North America and in Western Europe. Due to higher toxin production of *C. difficile* 027, infections result in increased mortality \[[@CR1]\].

Until now PCR-ribotyping has been the most effective and widely accepted molecular tool for typing of *C. difficile* strains. This provides the possibility of monitoring CDI outbreaks and the occurrence of hypervirulent strains.

Today matrix assisted laser desorption/ionization-time of flight mass spectroscopy (MALDI-TOF MS) provides an easy to handle system in order to identify different bacterial pathogens including *C. difficile* \[[@CR2], [@CR3]\]. MALDI-TOF MS is actually utilizable for determination of the bacterial species. There are only a few reports suggesting that MS can be applied for typing of MRSA \[[@CR4], [@CR5]\], *C. difficile* \[[@CR6]\] *Legionella* \[[@CR7], [@CR8]\] and *Pseudomonas* \[[@CR9]\].

We performed classical PCR-ribotyping of different *C. difficile* strains as well as typing via the extended SARAMIS™ MALDI-TOF system and found specific markers for ribotypes 001, 027 and 126/078 allowing clonal identification. Here we report on typing of the frequent *C. difficile* ribotypes 001, 027, 126 and 078 using MALDI-TOF MS.

Patients and methods {#Sec2}
====================

Laboratory and hospital settings {#Sec3}
--------------------------------

Synlab Medical Care Centre (Weiden, Germany) is located in a rural area in Southern Germany and analyses clinical samples from about 40 hospitals and more than 2,000 physicians serving outpatients in Northern Bavaria \[[@CR10]\]. In this region, CDI is known as an increasing nosocomial problem with sporadic severe cases \[[@CR10], [@CR11], [@CR12]\].

In the first half of 2009 we cultured approximately 500 *C. difficile* isolates from stool samples derived from in- and outpatients known with positive *C. difficile* toxin (Tcd) tests of stools.

Epidemiologic analysis of *C. difficile* in South Germany {#Sec4}
---------------------------------------------------------

Numbers of Tcd-positive stool samples and numbers of performed Tcd-tests were evaluated by the Hybase system (Cymed AG, Bochum, Germany) linked to the laboratory data system "promed open" (MCS, Eltville, Germany) as described before \[[@CR10]\].

*C. difficile* toxin analysis and culture {#Sec5}
-----------------------------------------

Stool samples were collected during 2009 and tested for *C. difficile*. Tcd examination and culture of *C. difficile* were performed as previously described \[[@CR11]\].

Identification of *C. difficile* was performed using the identification system for anaerobes "rapid ID 32 A system" (Biomérieux, Nürtingen, Germany) and by MALDI-TOF MS using the Bruker Daltonics microflex LT system (Bruker Daltonik GmbH, Bremen, Germany).

PCR ribotyping {#Sec6}
--------------

After extraction of bacterial DNA, amplification reactions were performed with specific primers according to Bidet et al. \[[@CR13]\]. In variation to this protocol, amplification reactions were performed in a 26.5 μl volume containing 15 μl H~2~O~bidest.~, 2.6 μl 10× FastStart Taq Polymerase PCR-buffer + MgCl~2~ (Roche), 1.25 μl of each primer, 0.25 μl dNTP (20 mM, Pharmacia), 0.15 μl FastStart Taq DNA polymerase (5 U/μl, Roche) and 6 μl template DNA. PCR was performed in a thermal cycler, for 1 cycle of 360 s at 95°C for initial denaturation and 40 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 45 s. Final extension was carried out for 180 s at 72°C.

Detection of PCR products {#Sec7}
-------------------------

Amplification products were separated using 8% polyacrylamide gels (for 2.5 h at 80 V, 21 mA in 1× TBE buffer). DNA banding patterns were visualized on a UV-transilluminator (Sigma) after staining for 15 min in ethidium bromide (20 μg/ml) and destaining for 5 min in H~2~O~bidest~. A molecular mass standard (DNA molecular weight marker VI, Roche) was included for normalization of the gel patterns. PCR ribotype profiles were compared to band patterns of 25 *C. difficile* reference strains (Cardiff-ECDC collection). *C. difficile* isolates that did not match one of the reference strains were sent for further typing to the German Reference Laboratory for Gastrointestinal Infections (University of Freiburg, Freiburg, Germany) or to Leiden University Medical Center (LUMC, Leiden, The Netherlands).

AXIMA\@SARAMIS™ MALDI-TOF MS {#Sec8}
----------------------------

MALDI-TOF MS for typing of *C. difficile* was performed in the laboratory of AnagnosTec Association for analytical biochemistry and diagnostics mbH (Zossen, Germany) according to the internal standard operating procedure.

After anaerobic cultivation of *C. difficile* isolates and examination of the culture morphology and purity, respective cells were transferred from blood-agar plates after 24 h growth at 37°C to a free spot on the FlexiMass-DS target using the direct smear method. Then, 1.0 μl alpha-cyano-4-hydroxy cinamic acid (CHCA) matrix solution was added to the samples within less than two minutes after transferring of cells to the target. The matrix solution (saturated CHCA in 33% ethanol, 33% acetonitrile, 3% triflouro acetic acid and 31% water) extracted the proteins. Afterwards, the matrix was dried at room temperature on the bench (not under air flow). Finally, the target was inserted into the mass spectrometer and spectra were generated by double-measurement with adequate quality control criteria. Mass analyses were performed in the linear mode with delayed, positive ion delayed extraction (acceleration voltage: 20 kV) on an AXIMA Confidence (Shimadzu Europe, Duisburg, Germany) mass spectrometer equipped with a nitrogen laser (λ = 337 nm). Spectra were accumulated from 500 automatically acquired laser pulse cycles. All spectra were processed by the BioTech Launchpad software (Shimadzu Europe, Duisburg, Germany) with baseline correction, peak filtering and smoothing. The resulting peak lists were exported to the SARAMIS™ software package. The spectra were compared to the superspectra for species identification. All spectra were transferred into the database for cluster analysis and biomarker analysis (Table [1](#Tab1){ref-type="table"}). Table 1Number of tested *C. difficile* isolates (double measurement) and distribution of the detected masses*green* specific masses of PCR-ribotype 001, *magenta* specific masses of PCR-ribotype 027, *blue* specific masses of PCR-ribotypes 078 and 126, *yellow* highly frequent masses among sporadic strains, *RT* ribotype, *m/z* mass-to-charge-relation

Results and discussion {#Sec9}
======================

Development of a MALDI-TOF database using ECDC-Brazier collection {#Sec10}
-----------------------------------------------------------------

Using the ECDC-Brazier collection encompassing 25 different PCR ribotypes we developed an initial reference database. After recording the mass spectra of each isolate by AXIMA\@SARAMIS™ MALDI-TOF MS the data were stored along with the information of PCR ribotypes in a SARAMIS™ database (Spectral Archive and Microbial Identification System). An internal calculation algorithm (Superspectra™ function for selection of specific biomarkers) was applied to recognize if certain peaks or combinations of certain peaks might be associated with specific PCR ribotypes. After identification of frequently occurring masses indicative for a certain subtype, it was examined how many "indicative masses" have to be determined in combination with the system to automatically recognize the respective ribotype. Masses of ribosomal protein fragments observed by MALDI-TOF MS analyses applied to the 25 reference PCR ribotypes are summarized in Table [1](#Tab1){ref-type="table"}. Using this database, four individual PCR ribotypes could be recognized (Table [1](#Tab1){ref-type="table"}). Types other than 001, 027 and 078/126 could not be separated due to the lack of specific masses.

Results of the analysis of 355 German clinical isolates {#Sec11}
-------------------------------------------------------

Ribotyping was performed on 355 *C. difficile* isolates, collected in the first half of 2009, revealing 29 different ribotypes. At least 330 isolates were clinical isolates from patients. Our *C. difficile* collection from patients showed the following constitution:

Ribotype (RT) 001 (*n* = 248; 70.0%) was the most prevalent strain, followed by RT 027 (*n* = 17; 4.8%), RT 078, 015 (*n* = 7; 2.0%), RT 126 (*n* = 6; 2.7%), RT 095 (*n *= 5; 1.4%), RT 77 (*n* = 4; 1.1%), RT 003, 014, 017, 023, (*n* = 3; 0.9%), RT 002, 029, 045, 046, 070, 081, 149 (*n* = 2; 0.6%), and RT 005, 012, 020, 053, 056, 075, 087, 106, 117, 131 (*n* = 1; 0.3%).

Figure [1](#Fig1){ref-type="fig"} shows spectra representative for the most common strains 001, 027 and 126/078. Stars show indicative masses for the respective ribotype. Fig. 1Overview of the mass spectra of *C. difficile* PCR-ribotypes 001 (**A**), 027 (**B**) and 126/078 (**C**) in comparison to the mass spectrum of *Clostridium orbiscindens* (**D**). Each peak represents the mass of an intact protein detected in the analyses while the height of the peak depends on the amount of proteins measured. Specific masses are indicated by stars. *RT* ribotype, *Int.* intensity, *m/z* mass-to-charge-relation

Validation of the MALDI-TOF MS database with 355 German isolates {#Sec12}
----------------------------------------------------------------

On the basis of the specific masses found for ribotypes 001, 027 and 078/126 (see Table [1](#Tab1){ref-type="table"}) we verified our database on the collected German isolates. While masses in yellow fields were not indicative for the given strains, masses in green fields were indicative for *C. difficile* 001 (*n* = 248), masses in magenta fields for *C. difficile* 027 (*n* = 17) and masses in blue fields for *C. difficile* 126/078 (*n* = 6/7).

All 001 isolates (*n* = 248) were recognized by the presence of 9--18 of the "green masses". The definition of less than nine masses resulted such that strains other than 001 were erroneously matched to *C. difficile* 001 while determination of more than 18 masses resulted in disregarding 001 isolates.

To identify 027 isolates, definition of the three "magenta masses" was sufficient using ten strains of ribotypes 027. Using this setting *C. difficile* 027 provided from German Robert-Koch-Institute (*n* = 7) were also correctly identified.

Because of the high molecular similarity of ribotype 126 and the hypervirulent strain 078, only PCR-ribotyping was able to discriminate between these two strains. Generated mass spectra of ribotypes 126 and 078 showed that both strains share seven specific "blue masses". Thus, typing of ribotypes 126 and 078 was sufficient for verification of the group of ribotypes 126/078.

Recently it was noticed that *C. difficile* strains 001, 017 and 027 were associated with fatal outcome in Germany \[[@CR14]\]. As demonstrated here, strains 001 and 027 might be identified simultaneously to *C. difficile* identification when using MALDI-TOF MS. However, due to the low number of 017 isolates it was not possible to identify diagnostic peaks for this strain. Although this limitation counts for other sporadic strains found in our region, 98.9% of the isolates (268 of 271) belonging to types 001, 027 and 078/126 were identified correctly by MALDI-TOF MS.

However, the finding that most strains were isolated only sporadically (\<10 isolates per strain per 6 months) implies that it was not possible to determine specific masses for these strains. On the other hand, in a population exhibiting a different composition of *C. difficile* strains, strains other than 001, 027 and 126 might be isolated in high numbers probably allowing strain identification by MALDI-TOF MS. Consequently, and besides technical conditions, identification of *C. difficile* strains by MALDI-TOFMS also depends on the prevalence of certain strains within a region.

However, one observation limits usage of our settings for application in other regions. Although the 027 isolates from the Robert-Koch-Institute were correctly identified when using 027 identification criteria (e.g. the three magenta masses), they also shared masses of ribotype 001. The 027 isolates (*n* = 7) from the Robert-Koch Institute derived from regions other than Northern Bavaria in Germany indicating regional specificity of *C. difficile* MALDI-TOF MS spectra. Hence, determination of regional settings for *C. difficile* strain identification by MALDI-TOF MS is essential. Furthermore, it also seems necessary to monitor strain identification by both MALDI-TOF MS and ribotyping over time to notice variation of spectra of *C. difficile* strains.

Analysing *C. difficile* by the Bruker Daltonics microflex LT system (Bruker Daltonik GmbH, Bremen, Germany) resulted in correct species identification. However, in our laboratory it was not possible to identify different ribotype strains. Recently, preliminary results of a study have been presented in which the Bruker system correctly recognized *C. difficile* PCR ribotypes 027 and 078 after composition of a new database encompassing at least ten spectra of each type \[[@CR6]\].

We were able to type *C. difficile* isolates using an extended MALDI-TOF MS system and we identified specific markers for the most frequent *C. difficile* ribotype 001 in Southern Germany including the highly virulent strain NAP1/027. However, typing of other, more sporadic strains was not possible due to the lack of sufficient numbers of *C. difficile* isolates. In order to use this effective system for typing of more sporadic strains as well, future work will have to analyze more isolates of the respective ribotypes to generate a broad database of reference mass spectra. In the end, MALDI-typing will provide a suitable tool for *C. difficile* strains and surveillance of CDI.
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